APOA1 and atherosclerosis: Furthermore, pre-clinical [18] and clinical [19] studies have previously shown that intravascular infusions of synthetic HDL containing a genetic variant of ApoA-I, ApoA-I Milano (ApoA-IM), inhibit progression and induce rapid regression and remodelling of atherosclerosis.